Research Project
Grant-in-Aid for Scientific Research (C)
Ameloblastoma is a benign and the most common odontogenic neoplasm, whereas high recurrence rates and possible malignant development have been reported. In the present study, we established two immortalized cell lines, termed HAM1 and 2, by transfecting of human telomerase reverse transcriptase (hTERT) gene and human papillomavirus-16 (HPV16) E6/E7 genes into primary in vitro outgrowths from follicular and desmoplastic ameloblastoma specimens. Both lines could growth in vivo not only as a result of orthotopic (HAM1, 100% ; HAM2, 100%) but also of ectopic (HAM1, 33% ; HAM2, 100%) implantation. The histological findings of these inoculated tissues showed that these cell lines retained the clinical manifestations of ameloblastoma well. These cell lines are, to the best of our knowledge, the first in vitro / in vivo model system that can form recognizable tissue structures as human ameloblastoma in vivo. Then, we analyzed expression of some cancer-related molecules in these cell lines, and selected a candidate gene showed the highest expression frequency (100%) in RT-PCR analysis of eight primary ameloblastoma cases. An immunohistochemical study also demonstrated that the production of the candidate gene was considerably increased in 34 of 65 primary ameloblastoma specimens (52.3%). Moreover, a selective inhibitor for this candidate gene showed significant inhibitory effects on these cell lines in vitro and in vivo. Our study clearly supports that products of this candidate gene can make one of the molecular targets in treatment of ameloblastoma.
All 2006 2005 2004
All Journal Article (11 results)
ゲノム医学 6
Pages: 23-29
Immunology 116
Pages: 53-63
Immunology(Corresponding author) 116
Br. J. Dermatol. 151
Pages: 472-480
Biochem. Biophys. Res. Commun. 314
Pages: 313-320
Biochem.Biophys.Res.Commun. 314
Br.J.Dermatol.(Corresponding author) 151
Br.J.Dermatol. 151
